![Transparency Market Researchが調査・発行した産業分析レポートです。急性ウイルス性副鼻腔炎治療の世界市場2021年ｰ2031年：治療別（生理食塩水点鼻薬、鼻用コルチコステロイド、充血除去薬、NSAID、その他）、投与経路別、流通チャネル別、感染タイプ別 / Acute Viral Rhinosinusitis Treatment Market (Treatment: Saline Nasal Spray, Nasal Corticosteroids, Decongestants, NSAIDs, and Others; Route of Administration: Topical, Nasal, Oral, and Injectable; Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies; and Infection Type: Rhinovirus [Picornavirus] and Non-Rhinovirus) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2111A049資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-55.gif) | • レポートコード：MRC2111A049 • 出版社/出版日：Transparency Market Research / 2021年8月18日 • レポート形態：英文、PDF、254ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、急性ウイルス性副鼻腔炎治療の世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、治療別（生理食塩水点鼻薬、鼻用コルチコステロイド、充血除去薬、NSAID）分析、投与経路別分析、流通チャネル別分析、感染タイプ別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・急性ウイルス性副鼻腔炎治療の世界市場規模：治療別（生理食塩水点鼻薬、鼻用コルチコステロイド、充血除去薬、NSAID） ・急性ウイルス性副鼻腔炎治療の世界市場規模：投与経路別 ・急性ウイルス性副鼻腔炎治療の世界市場規模：流通チャネル別 ・急性ウイルス性副鼻腔炎治療の世界市場規模：感染タイプ別 ・急性ウイルス性副鼻腔炎治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Acute Viral Rhinosinusitis Treatment Market – Scope of Report
TMR’s report on the global acute viral rhinosinusitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the global acute viral rhinosinusitis treatment market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute viral rhinosinusitis treatment market from 2021 to 2031.
The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global acute viral rhinosinusitis treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global acute viral rhinosinusitis treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global acute viral rhinosinusitis treatment market. These serve as valuable tools for existing market players as well as entities interested in participating in the global acute viral rhinosinusitis treatment market.
The report also delves into the competitive landscape of the global acute viral rhinosinusitis treatment market. Key players operating in the global acute viral rhinosinusitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute viral rhinosinusitis treatment market that have been profiled in this report.
Key Questions Answered in Acute Viral Rhinosinusitis Treatment Report
What is the sales/revenue generated by acute viral rhinosinusitis treatment products across all regions during the forecast period?
What are the opportunities in the global acute viral rhinosinusitis treatment market?
What are major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which treatment product segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Acute Viral Rhinosinusitis Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global acute viral rhinosinusitis treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of treatments.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global acute viral rhinosinusitis treatment market in terms of treatment, route of administration, distribution channel, infection type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global acute viral rhinosinusitis treatment market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Viral Rhinosinusitis Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
6.2.1. Saline Nasal Spray
6.2.2. Nasal Corticosteroids
6.2.2.1. Fluticasone
6.2.2.2. Budesonide
6.2.2.3. Mometasone
6.2.2.4. Others
6.2.3. Decongestants
6.2.3.1. Topical Decongestants
6.2.3.2. Systemic Decongestants
6.2.4. NSAIDs
6.2.4.1. Acetaminophen
6.2.4.2. Ibuprofen
6.2.4.3. Aspirin
6.2.4.4. Others
6.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration
7. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
7.2.1. Acute Viral Rhinosinusitis Treatment
7.2.1.1. Topical
7.2.1.2. Nasal
7.2.1.3. Oral
7.2.1.4. Injectable
7.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.2.1. Acute Viral Rhinosinusitis Treatment
8.2.1.1. Online Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Hospital Pharmacies
8.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Infection Type
9.1. Introduction & Definition
9.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
9.2.1. Rhinovirus (Picornavirus)
9.2.2. Non-Rhinovirus
9.2.2.1. Influenza
9.2.2.2. Enterovirus
9.2.2.3. Adenovirus
9.2.2.4. Others
9.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Infection Type
10. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Region
11. North America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
11.1. Introduction
11.2. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
11.2.1. Saline Nasal Spray
11.2.2. Nasal Corticosteroids
11.2.2.1. Fluticasone
11.2.2.2. Budesonide
11.2.2.3. Mometasone
11.2.2.4. Others
11.2.3. Decongestants
11.2.3.1. Topical Decongestants
11.2.3.2. Systemic Decongestants
11.2.4. NSAIDs
11.2.4.1. Acetaminophen
11.2.4.2. Ibuprofen
11.2.4.3. Aspirin
11.2.4.4. Others
11.2.5. Others
11.3. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
11.3.1. Acute Viral Rhinosinusitis Treatment
11.3.1.1. Topical
11.3.1.2. Nasal
11.3.1.3. Oral
11.3.1.4. Injectable
11.4. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Acute Viral Rhinosinusitis Treatment
11.4.1.1. Online Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Hospital Pharmacies
11.5. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
11.5.1. Rhinovirus (Picornavirus)
11.5.2. Non-Rhinovirus
11.5.2.1. Influenza
11.5.2.2. Enterovirus
11.5.2.3. Adenovirus
11.5.2.4. Others
11.6. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. Infection Type
11.7.5. By Country
12. Europe Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
12.2.1. Saline Nasal Spray
12.2.2. Nasal Corticosteroids
12.2.2.1. Fluticasone
12.2.2.2. Budesonide
12.2.2.3. Mometasone
12.2.2.4. Others
12.2.3. Decongestants
12.2.3.1. Topical Decongestants
12.2.3.2. Systemic Decongestants
12.2.4. NSAIDs
12.2.4.1. Acetaminophen
12.2.4.2. Ibuprofen
12.2.4.3. Aspirin
12.2.4.4. Others
12.2.5. Others
12.3. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
12.3.1.1. Topical
12.3.1.2. Nasal
12.3.1.3. Oral
12.3.1.4. Injectable
12.4. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1.1. Online Pharmacies
12.4.1.2. Retail Pharmacies
12.4.1.3. Hospital Pharmacies
12.5. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
12.5.1. Rhinovirus (Picornavirus)
12.5.2. Non-Rhinovirus
12.5.2.1. Influenza
12.5.2.2. Enterovirus
12.5.2.3. Adenovirus
12.5.2.4. Others
12.6. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Infection Type
12.7.5. By Country/Sub-region
13. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
13.2.1. Saline Nasal Spray
13.2.2. Nasal Corticosteroids
13.2.2.1. Fluticasone
13.2.2.2. Budesonide
13.2.2.3. Mometasone
13.2.2.4. Others
13.2.3. Decongestants
13.2.3.1. Topical Decongestants
13.2.3.2. Systemic Decongestants
13.2.4. NSAIDs
13.2.4.1. Acetaminophen
13.2.4.2. Ibuprofen
13.2.4.3. Aspirin
13.2.4.4. Others
13.2.5. Others
13.3. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
13.3.1.1. Topical
13.3.1.2. Nasal
13.3.1.3. Oral
13.3.1.4. Injectable
13.4. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1.1. Online Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Hospital Pharmacies
13.5. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
13.5.1. Rhinovirus (Picornavirus)
13.5.2. Non-Rhinovirus
13.5.2.1. Influenza
13.5.2.2. Enterovirus
13.5.2.3. Adenovirus
13.5.2.4. Others
13.6. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
13.7.1. By Treatment
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. Infection Type
13.7.5. By Country/Sub-region
14. Latin America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
14.2.1. Saline Nasal Spray
14.2.2. Nasal Corticosteroids
14.2.2.1. Fluticasone
14.2.2.2. Budesonide
14.2.2.3. Mometasone
14.2.2.4. Others
14.2.3. Decongestants
14.2.3.1. Topical Decongestants
14.2.3.2. Systemic Decongestants
14.2.4. NSAIDs
14.2.4.1. Acetaminophen
14.2.4.2. Ibuprofen
14.2.4.3. Aspirin
14.2.4.4. Others
14.2.5. Others
14.3. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
14.3.1.1. Topical
14.3.1.2. Nasal
14.3.1.3. Oral
14.3.1.4. Injectable
14.4. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1.1. Online Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Hospital Pharmacies
14.5. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
14.5.1. Rhinovirus (Picornavirus)
14.5.2. Non-Rhinovirus
14.5.2.1. Influenza
14.5.2.2. Enterovirus
14.5.2.3. Adenovirus
14.5.2.4. Others
14.6. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. Infection Type
14.7.5. By Country/Sub-region
15. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
15.2.1. Saline Nasal Spray
15.2.2. Nasal Corticosteroids
15.2.2.1. Fluticasone
15.2.2.2. Budesonide
15.2.2.3. Mometasone
15.2.2.4. Others
15.2.3. Decongestants
15.2.3.1. Topical Decongestants
15.2.3.2. Systemic Decongestants
15.2.4. NSAIDs
15.2.4.1. Acetaminophen
15.2.4.2. Ibuprofen
15.2.4.3. Aspirin
15.2.4.4. Others
15.2.5. Others
15.3. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
15.3.1.1. Topical
15.3.1.2. Nasal
15.3.1.3. Oral
15.3.1.4. Injectable
15.4. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
15.4.1. Acute Viral Rhinosinusitis Treatment
15.4.1.1. Online Pharmacies
15.4.1.2. Retail Pharmacies
15.4.1.3. Hospital Pharmacies
15.5. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
15.5.1. Rhinovirus (Picornavirus)
15.5.2. Non-Rhinovirus
15.5.2.1. Influenza
15.5.2.2. Enterovirus
15.5.2.3. Adenovirus
15.5.2.4. Others
15.6. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
15.7.1. By Treatment
15.7.2. By Route of Administration
15.7.3. By Distribution Channel
15.7.4. By Infection Type
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Position Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sun Pharmaceutical Industries, Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Pfizer Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. Fresenius Kabi USA, LLC.
16.2.4.1. Company Overview (HQ, Business Segments)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Dr. Reddy’s Laboratories, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. Novartis AG
16.2.6.1. Company Overview (HQ, Business Segments)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd.
16.2.7.1. Company Overview (HQ, Business Segments)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Sanofi
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Abbott Laboratories
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Bayer AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Eli Lilly And Company
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Bristol-Myers Squibb
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Merck & Co, Inc.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. AstraZeneca Plc
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
16.2.15. Amneal Pharmaceuticals LLC
16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.15.2. Growth Strategies
16.2.15.3. SWOT Analysis
16.2.16. GlaxoSmithKline plc
16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.16.2. Growth Strategies
16.2.16.3. SWOT Analysis
16.2.17. Aurobindo Pharma
16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.17.2. Growth Strategies
16.2.17.3. SWOT Analysis
16.2.18. Hikma Pharmaceuticals plc
16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.18.2. Growth Strategies
16.2.18.3. SWOT Analysis
16.2.19. Wockhardt
16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.19.2. Growth Strategies
16.2.19.3. SWOT Analysis
16.2.20. Mylan N.V.
16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.20.2. Growth Strategies
16.2.20.3. SWOT Analysis
Table 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 03: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 09: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 10: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 11: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 12: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 13: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 14: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 15: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 18: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 19: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 22: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 23: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 24: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 27: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 28: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 29: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 30: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 31: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 32: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 33: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 34: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 35: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 36: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 37: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 38: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 39: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 40: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 41: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 42: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 43: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 44: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 45: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 46: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 47: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 48: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 49: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 50: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 51: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 52: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 53: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 54: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031